Navigation Links
CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
Date:10/26/2007

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States.

The inducement stock options cover an aggregate 23,600 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10 year term and vest over four years as follows: 20 percent of these options will vest on the date one year from the optionee's hire date, 20 percent of the options will vest in monthly increments during each of the second and third years, and 40 percent of the options will vest in monthly increments during the fourth year (in all cases subject to the terms and conditions of CV Therapeutics 2004 Employment Commencement Incentive Plan).

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. Sonic Foundry reports GAAP loss as Q2 revenues rise
4. Fiserv reports $113.5 million in Q1 profit
5. Third Wave reports net loss of $18.9M for 2006
6. Musicnotes reports 45 percent growth in 2006
7. Sonic Foundry reports net loss, higher revenue
8. Sonic Foundry reports first cash-positive quarter
9. Merge Healthcare reports $10.8M net loss in Q3
10. Third Wave reports $5.2M third quarter loss
11. Merge Healthcare appoints new CEO, reports $215 million Q2 loss

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., Congruent Software agre...(including project accounting clients) to Synergy ... Seattle, WA (PRWEB) Decem...d today it has acquired the Microsoft Dynamics SL ...iness technology provider. The move was necessary ...
(Date:12/1/2009)..., , SAN DIEGO, Dec. 1 /PRNewswir...n Board: AEMD) announced today that it will presen... 3, 2009 at 2:00 p.m. (PST) at the Luxe Hotel in L...mes A. Joyce, will present a corporate overview an... progress for its lead product, the Hemopurifier&#...
(Date:12/1/2009)..., , INDIANAPOLIS and NORTH VANCOUVER, Br...ow AgroSciences LLC, a wholly owned subsidiary of ...oma Biosciences, Inc. today announced the signing ...ent. The agreement provides Dow AgroSciences with ...Loci (ETL) technology on an exclusive basis in maj...
(Date:12/1/2009)..., , SAN FRANCISCO, Dec. 1 /PRNewswire-Fi...etin Board: MZEI) announced today that in tests in..., it continues to break "6 log" decontamination ba...rming bacteria, Claustridium difficile and Bacilli...cSure(TM) as an extremely potent sporicidal techno...
Breaking Biology Technology:Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3Aethlon Medical to Present at LD MICRO Conference on December 3, 2009 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 2Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops 3Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2
...hnson Controls reported net income of $165 million...tly from the $168 million it made in the same peri... bolstered by quarterly sales of $7.5 billion, up ...ions of York International and Delphi,s battery bu... movements away from the beleaguered auto industry...
... of weeks, we have been retrospectively reviewing ...s, including our Midwest ones, during 2005. This r...reflected in a stock price and resultant valuation...k at and value the impact of our industry. One suc...00 Best Companies to Work For 2006 published on J...
... is more information and technology out there than...Credit Union Executives Society, choosing the righ... in the market. , ,Marketing has to change and tak..., Gibler said, citing the endless amount of ads, e...n demand that demands a users attention. All these...
Other Biology Technology:Biotech leads list of top U.S. companies to work for 2Biotech leads list of top U.S. companies to work for 3Biotech leads list of top U.S. companies to work for 4Biotech leads list of top U.S. companies to work for 5Exec focuses on blogs as business tool 2
(Date:12/1/2009)... OptiNose is pleased to announce the publication o...gating the efficacy and tolerability of its novel,...eatment of chronic rhinosinusitis with nasal polyp...rnational and European Rhinologic Societies. , ...nic disease that can significantly reduce a patien...
(Date:12/1/2009)...titute of Technology has been awarded a U.S. Air F... for energy harvesting and adaptive materials, and...rocesses of the modern warfighter. , The $10.5 ...ganic/Organic Nanostructures and Improved Cognitio...k and Kenneth Sandhage, professors in Georgia Tech...
(Date:12/1/2009)... a Monash University-led international research te...tput of the next generation of solar cells. , Sc...th colleagues from the universities of Wollongong ...tised solar cells with a three-fold increase in en...y reported tandem dye-sensitised solar cells. , ...
Breaking Biology News(10 mins):New data on highly effective treatment for chronic rhinosinusitis with nasal polyps 2Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4Innovation puts next-generation solar cells on the horizon 2Hilary Smith Upped to Senior Vice President Communications NBC Universal Women 26 Lifestyle Entertainment Networks 51698 1Hilary Smith Upped to Senior Vice President Communications NBC Universal Women 26 Lifestyle Entertainment Networks 51698 2LCA Congratulates Nominee For Surgeon General 51696 1LCA Congratulates Nominee For Surgeon General 51696 2New RISI Report Analyzes South American Tree Farm and Biomass Energy Investment Opportunities 13027 1New RISI Report Analyzes South American Tree Farm and Biomass Energy Investment Opportunities 13027 2New RISI Report Analyzes South American Tree Farm and Biomass Energy Investment Opportunities 13027 3
...BOSTONWith unprecedented sensitivity, Carnegie Mel...viral particles and bulky von Willebrand factors u...ults may lead to new biological discoveries and re...sing mass spectrometry. , This is a new frontier ...e research professor and director of the Center fo...
... A nanoparticle drug delivery system designed for ... selectivity in a novel cell culture model devised...ct, conducted jointly in the Schools of Pharmacy, ... featured in the September issue of the Experiment...s is particularly difficult for a number of reason...
... Restless legs syndrome is a common problem in chi...s and the United Kingdom, according to a new repor...arly 2 percent of children aged 8 to 17 are affect...ce moderate to severe symptoms, including sleep di...n the August issue of the journal Pediatrics. , T...
Other Biology News:Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor 2Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor 3Novel 3-D cell culture model shows selective tumor uptake of nanoparticles 2Restless legs syndrome affects nearly 2 percent of US/UK children 2Restless legs syndrome affects nearly 2 percent of US/UK children 3
Thermal Printer Paper from Promega
...man, Assay, 96 wells. ELISA.Specific for total MM...ed MMP-3. No cross-reactivity with MMP-1, -2, -9. ...table for use with cell culture supernatant, serum...t -15 to -30 C. Category: Drug Screening & Cellul...
Dr. P Set - Human Fetal Normal Tissue: Umbilical Cord from BioChain
Rabbit Anti-Human INHBB Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: